- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Novo-Nordisk gets CDSCO Panel nod to study Human Growth Hormone Analogue Somapacitan
New Delhi: In line with the pharmaceutical major Novo-Nordisk's proposed protocol amendment on the study of human growth hormone Somapacitan, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has granted permission for the conduct of the trial as per the proposed amended protocol.
This came after the firm presented the proposed protocol amendment version 8.0 dated 08MAR2022 under the REAL 5 protocol no. NN8640-4245, before the committee.
Somapacitan is a human growth hormone analogue for subcutaneous injection and is indicated for adults with growth hormone deficiency.
Growth hormone deficiency is a disorder characterized by inadequate growth hormone production from the anterior pituitary gland, a small gland located at the base of the brain that produces several hormones. Adult patients with growth hormone deficiency can receive growth hormone as a replacement therapy.
Somapacitan binds to the growth hormone receptor and induces intracellular signalling to up-regulate insulin-like growth factor I (IGF-1). IGF-1 causes growth in bones and muscle tissue. Growth hormones more directly cause the fusion of myoblasts and myotubes to cause muscle fibre growth, activate neural stem cells, and induce chondrocyte proliferation.
Earlier, the Medical Dialogues Team had reported that the Food and Drug Administration (FDA) had approved Sogroya (somapacitan-beco; Novo Nordisk) injection for the replacement of endogenous growth hormone in adults with growth hormone deficiency.
At the recent SEC meeting for Endocrinology and Metabolism held on September 9th, 2022, the expert panel reviewed the proposed protocol amendment version 8.0 dated 08MAR2022 under the REAL 5 protocol no. NN8640-4245, presented by pharmaceutical major Novo-Nordisk.
After detailed deliberation, the committee recommended the grant of permission to conduct the trial of the human growth hormone Somapacitan as per the proposed amended protocol.
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.